398 related articles for article (PubMed ID: 26662313)
1. miR-27a regulates the sensitivity of breast cancer cells to cisplatin treatment via BAK-SMAC/DIABLO-XIAP axis.
Zhou S; Huang Q; Zheng S; Lin K; You J; Zhang X
Tumour Biol; 2016 May; 37(5):6837-45. PubMed ID: 26662313
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of miR-221 promotes the cisplatin-inducing apoptosis by targeting the BIM-Bax/Bak axis in breast cancer.
Ye Z; Hao R; Cai Y; Wang X; Huang G
Tumour Biol; 2016 Apr; 37(4):4509-15. PubMed ID: 26503209
[TBL] [Abstract][Full Text] [Related]
3. Bax/Bak-dependent, Drp1-independent Targeting of X-linked Inhibitor of Apoptosis Protein (XIAP) into Inner Mitochondrial Compartments Counteracts Smac/DIABLO-dependent Effector Caspase Activation.
Hamacher-Brady A; Brady NR
J Biol Chem; 2015 Sep; 290(36):22005-18. PubMed ID: 26134559
[TBL] [Abstract][Full Text] [Related]
4. In vivo and in vitro effects of microRNA-27a on proliferation, migration and invasion of breast cancer cells through targeting of SFRP1 gene via Wnt/β-catenin signaling pathway.
Kong LY; Xue M; Zhang QC; Su CF
Oncotarget; 2017 Feb; 8(9):15507-15519. PubMed ID: 28099945
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
Zhang X; Huang L; Zhao Y; Tan W
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
[TBL] [Abstract][Full Text] [Related]
6. Transfection of Smac/DIABLO sensitizes drug-resistant tumor cells to TRAIL or paclitaxel-induced apoptosis in vitro.
Mao HL; Liu PS; Zheng JF; Zhang PH; Zhou LG; Xin G; Liu C
Pharmacol Res; 2007 Dec; 56(6):483-92. PubMed ID: 18029193
[TBL] [Abstract][Full Text] [Related]
7. Role of XIAP in inhibiting cisplatin-induced caspase activation in non-small cell lung cancer cells: a small molecule Smac mimic sensitizes for chemotherapy-induced apoptosis by enhancing caspase-3 activation.
Checinska A; Hoogeland BS; Rodriguez JA; Giaccone G; Kruyt FA
Exp Cell Res; 2007 Apr; 313(6):1215-24. PubMed ID: 17291493
[TBL] [Abstract][Full Text] [Related]
8. Bypassing the need for pre-sensitization of cancer cells for anticancer TRAIL therapy with secretion of novel cell penetrable form of Smac from hA-MSCs as cellular delivery vehicle.
Khorashadizadeh M; Soleimani M; Khanahmad H; Fallah A; Naderi M; Khorramizadeh M
Tumour Biol; 2015 Jun; 36(6):4213-21. PubMed ID: 25586349
[TBL] [Abstract][Full Text] [Related]
9. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Xu K; Yagüe E
Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
[TBL] [Abstract][Full Text] [Related]
10. Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells.
Fandy TE; Shankar S; Srivastava RK
Mol Cancer; 2008 Jun; 7():60. PubMed ID: 18590557
[TBL] [Abstract][Full Text] [Related]
11. X-linked inhibitor regulating TRAIL-induced apoptosis in chemoresistant human primary glioblastoma cells.
Roa WH; Chen H; Fulton D; Gulavita S; Shaw A; Th'ng J; Farr-Jones M; Moore R; Petruk K
Clin Invest Med; 2003 Oct; 26(5):231-42. PubMed ID: 14596484
[TBL] [Abstract][Full Text] [Related]
12. Disturbed expression of the apoptosis regulators XIAP, XAF1, and Smac/DIABLO in gastric adenocarcinomas.
Shibata T; Mahotka C; Wethkamp N; Heikaus S; Gabbert HE; Ramp U
Diagn Mol Pathol; 2007 Mar; 16(1):1-8. PubMed ID: 17471152
[TBL] [Abstract][Full Text] [Related]
13. MiR-944 functions as a novel oncogene and regulates the chemoresistance in breast cancer.
He H; Tian W; Chen H; Jiang K
Tumour Biol; 2016 Feb; 37(2):1599-607. PubMed ID: 26298722
[TBL] [Abstract][Full Text] [Related]
14. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells.
Bockbrader KM; Tan M; Sun Y
Oncogene; 2005 Nov; 24(49):7381-8. PubMed ID: 16044155
[TBL] [Abstract][Full Text] [Related]
15. miR-27a-mediated antiproliferative effects of metformin on the breast cancer cell line MCF-7.
Zhao W; Zhang X; Liu J; Sun B; Tang H; Zhang H
Oncol Rep; 2016 Dec; 36(6):3691-3699. PubMed ID: 27779715
[TBL] [Abstract][Full Text] [Related]
16. MiR-519d impedes cisplatin-resistance in breast cancer stem cells by down-regulating the expression of MCL-1.
Xie Q; Wang S; Zhao Y; Zhang Z; Qin C; Yang X
Oncotarget; 2017 Mar; 8(13):22003-22013. PubMed ID: 28423543
[TBL] [Abstract][Full Text] [Related]
17. Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.
Zhao JJ; Chu ZB; Hu Y; Lin J; Wang Z; Jiang M; Chen M; Wang X; Kang Y; Zhou Y; Ni Chonghaile T; Johncilla ME; Tai YT; Cheng JQ; Letai A; Munshi NC; Anderson KC; Carrasco RD
Cancer Res; 2015 Oct; 75(20):4384-4397. PubMed ID: 26249174
[TBL] [Abstract][Full Text] [Related]
18. Mir-1307 regulates cisplatin resistance by targeting Mdm4 in breast cancer expressing wild type P53.
Wang X; Zhu J
Thorac Cancer; 2018 Jun; 9(6):676-683. PubMed ID: 29697201
[TBL] [Abstract][Full Text] [Related]
19. MiR-181b promotes chemoresistance in breast cancer by regulating Bim expression.
Zheng Y; Lv X; Wang X; Wang B; Shao X; Huang Y; Shi L; Chen Z; Huang J; Huang P
Oncol Rep; 2016 Feb; 35(2):683-90. PubMed ID: 26572075
[TBL] [Abstract][Full Text] [Related]
20. MiR-363 sensitizes cisplatin-induced apoptosis targeting in Mcl-1 in breast cancer.
Zhang R; Li Y; Dong X; Peng L; Nie X
Med Oncol; 2014 Dec; 31(12):347. PubMed ID: 25416050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
